| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| fasinumab | nerve growth factor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neuralgia[MeSHID:D009437] Degenerative polyarthritis[MeSHID:D010003] Low Back Pain[MeSHID:D017116] Pain[MeSHID:D010146] |
25.46 | phase 3 | inhibitor |
| fasinumab | nerve growth factor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neuralgia[MeSHID:D009437] Degenerative polyarthritis[MeSHID:D010003] Low Back Pain[MeSHID:D017116] Pain[MeSHID:D010146] |
25.46 | phase 3 | unknown |
| fasinumab | beta-nerve growth factor | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neuralgia[MeSHID:D009437] Degenerative polyarthritis[MeSHID:D010003] Low Back Pain[MeSHID:D017116] Pain[MeSHID:D010146] |
25.46 | investigational | inhibitor |
| click here to return to the previous page | ||||||||